Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol induction in Crohn's disease
NCT00552058Phase 3Completed
- Sponsor
- UCB
- Start
- Mar 2008
- Primary completion
- Oct 2009
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Certolizumab pegol with Placebo (2 arms). Primary endpoint: Percentage of Subjects in Clinical Remission at 6 weeks. Started Mar 2008; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00552058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00552058.